Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells

Qayum, Arem; Magotra, Asmita; Shah, Syed Mohmad; Nandi, Utpal; Sharma, Paresh; Shah, Bhahwal Ali; Singh, Shashank

doi:10.1016/j.heliyon.2022.e09103

Cited by 7 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some studies, cancer spheroids have been used to study the mechanisms involved in drug activity or resistance, which also supports the identification of synergistic drug combinations [ 207 , 208 ]. For example, Dubois et al developed spheroids from two triple-negative breast cancer cell lines (i.e., MDA-MB-231 and SUM1315) and used them to determine the effectiveness of co-treatment with Olaparib and fractionated irradiation with the aim of optimizing the balance between Olaparib cytotoxicity and resistance [ 146 , 180 , 207 ].…”

Section: Applications Of 3d Cancer In Vitro Models To Drug Developmentmentioning

confidence: 99%

Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment

et al. 2023

View full text Add to dashboard Cite

In the last decades three-dimensional (3D) in vitro cancer models have been proposed as a bridge between bidimensional (2D) cell cultures and in vivo animal models, the gold standards in the preclinical assessment of anticancer drug efficacy. 3D in vitro cancer models can be generated through a multitude of techniques, from both immortalized cancer cell lines and primary patient-derived tumor tissue. Among them, spheroids and organoids represent the most versatile and promising models, as they faithfully recapitulate the complexity and heterogeneity of human cancers. Although their recent applications include drug screening programs and personalized medicine, 3D in vitro cancer models have not yet been established as preclinical tools for studying anticancer drug efficacy and supporting preclinical-to-clinical translation, which remains mainly based on animal experimentation. In this review, we describe the state-of-the-art of 3D in vitro cancer models for the efficacy evaluation of anticancer agents, focusing on their potential contribution to replace, reduce and refine animal experimentations, highlighting their strength and weakness, and discussing possible perspectives to overcome current challenges.

show abstract